Pathologic Intimal Hyperplasia as a Response to Vascular Injury and Reconstruction.

Slides:



Advertisements
Similar presentations
Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.
Advertisements

The value of DES in unprotected left main lesions has not been evaluated by dedicated randomized clinical trials. Especially, it is not known whether currently.
Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.
The TAXUS™ Paclitaxel-Eluting Stent Program. The safety and effectiveness of the TAXUS ™ Express 2 ™ Stent has not been established in patients with coronary.
Pathogenesis of Atherosclerosis Judith Berliner, Ph.D. Departments of Pathology and Medicine Division of Cardiology David Geffen School of Medicine at.
Stents Are Not Enough: Statins Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford.
PBL CV 2 Pathophysiology of coronary artery disease.
Inflammation Following Percutaneous Coronary Interventions Rabih R. Azar, MD, MSc, FACC Division of Cardiology Hotel Dieu de France Hospital.
HELICAL STE NTS C.G.Caro Department of Bioengineering Imperial College.
Θεματική ενότητα: Stenting Μ. Ματσάγκας, MD, PhD, FEBVS Σάββατο 9 Φεβρουαρίου 2013.
Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)
Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.
Drug Eluting Stents – The Cell Biology Andrew Newby BRISTOL HEART INSTITUTE ?
Coronary Involvement in Takayasu’s Arteritis Saori Kobayashi.
Angioplasty’s Fight against Restenosis: Drug Eluting Stents & Bare Metal Stents.
Coated stents: a new era Ulrich Sigwart MD Director, Cardiovascular Institute Royal Brompton Hospital London, United Kingdom Cindy Grines MD Director,
Lipoprotein Structures, Function and Metabolism (4)
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Atherosclerosis.
CURRENT CONCEPTS IN THE MANAGEMENT OF INTRACRANIAL ATHEROSCLEROTIC DISEASE Robert D. Ecker, M.D. ~Neurosurgery 59:S3-210-S3-218, 2006 Feb. 06, 07 VJ.
Antiplatelet Drugs - Principles Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
The Science Behind Taxus Advanced Angioplasty 2004 Christian Vander Velde, Boston Scientific Europe, Marketing.
7/9/08 Priya Pillutla, M.D. Cath Conference. History Priya Pillutla, MD HPI – 58 y/o M presented in May ‘08 w/escalating chest pressure at rest and with.
03/06/231 K June /06/232 Atherosclerosis Etiology Classic Risk Factors Dyslipidemia Low HDL Epidemiological Studies (e.g. Framingham) Genetic.
Excessive SMC growth within the vascular wall after trauma -proliferation -apoptosis -migration - accelerated matrix deposition major cause of failure.
Trials of radiation to prevent or reduce in-stent restenosis Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Atherosclerosis CVS lecture 2 Atherosclerosis Shaesta Naseem.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Atherosclerosis CVS 1 Hisham Al Khalidi. Atherosclerosis.wmv.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
Instent Restenosis and Late Stent Thrombosis Larry S. Dean, MD, FACC, FSCAI Professor of Medicine and Surgery University of Washington School of Medicine.
Radiation for restenosis: the dark side of arteries Robert S Schwartz MD Professor of Medicine Mayo Clinic Rochester, MN.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Atherosclerosis CVS lecture 2 Atherosclerosis. Vessel wall structure.
Dr.Hesham Rashid, MD PATHOGENIC MECHANISMS OF ATHEROSCLEROSIS
WHY TITAN WORKS AGAINST RESTENOSIS?. INTRODUCTION THE CELL MODEL THE HUMAN THE ANIMAL MODEL CONCLUSION WHY TITAN WORKS AGAINST RESTENOSIS ?
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
Pathology of Atherosclerosis
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
The Black Back Yard of D.E.S [D.ES Pitfalls) Ehud Grenadier M.D H.M.C, Assuta, Rambam Med. Ctrs. Israel The Black Back Yard of D.E.S [D.ES Pitfalls) Ehud.
Boston Scientific Drug eluting stent program A Scientific Approach Identify therapeutic agent Identify appropriate polymer carrier Evaluate a broad range.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Atherosclerosis Please read Robbins p
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Vascular Inflammation and Repair: Implications for.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
“The Percutaneous Revolution” The Surgeon’s Perspective William O
The American College of Cardiology Presented by Dr. Nikolaus Marx
From: Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal StentsThe TAXUS V ISR Randomized Trial JAMA. 2006;295(11):
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M
The OrbusNeich EPC Capture Biodegradable Polymer Sirolimus-eluting Stent Program Michael JB Kutryk, MD, PhD St Michael’s Hospital, Toronto.
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
Presented at ACC 2003 Late Breaking Clinical Trials
Fig 6.1 Drug released by diffusion
Stenting:επαναστένωση ISR (intra stent restenosis)
Drug-eluting stents for in-stent restenosis
The American College of Cardiology Presented by Dr. Nikolaus Marx
Figure 2 Protective functions of HDL
Atherosclerosis Dr:HAMED ALGHAMDI.
Integrin αvβ3 as a target in the prevention of neointimal hyperplasia
Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia—A review  Alexander W. Clowes, MD, Michael A. Reidy,
Presentation transcript:

Pathologic Intimal Hyperplasia as a Response to Vascular Injury and Reconstruction

Background Ebolectomy catheter induced intimal thickening (accumulation of smooth muscle cells [SMCs] and extracellular matrix) Balloon angioplasty – 30% coronary arteries develop marked restenosis after 6 months – fibrous with many SMCs

Background Carotid endarterectomy – intimal hyperplasia >50% stenosis in 10-20%, symptomatic in 1% Vascular grafts, reversed or in situ, autologous or synthetic

Background

The Problem Neointimal Hyperplasia Acute s/p PTCA, Elastic van Giesen stain 30 days s/p PTCA, Elastic van Giesen stain Schwartz et.al. Rev Cardiovasc Med. 2002;3:S4

The Problem Neointimal Hyperplasia Schwartz et.al. Rev Cardiovasc Med. 2002;3:S4 In-stent restenosis is almost exclusively the result of neointimal formation.

Pathophysiology Neointimal Hyperplasia Platelets accumulate on denuded region Endothelial cells proliferate SMCs also proliferate and migrate into intima, causingd intimal thickening

Pathophysiology Neointimal Hyperplasia New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima

Pathophysiology Neointimal Hyperplasia Conde et.al. Cath & Cardiovasc Int. 2003;60:236 New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima

Pathophysiology Neointimal Hyperplasia Conde et.al. Cath & Cardiovasc Int. 2003;60:236 New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima

Pathophysiology Neointimal Hyperplasia Conde et.al. Cath & Cardiovasc Int. 2003;60:236 New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima

Pathophysiology Neointimal Hyperplasia New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima

Pathophysiology Neointimal Hyperplasia Factors from platelets, leukocytes, smooth muscle cells, and extracellular matrix interact and regulate the process of intimal hyperplasia, making each step a potential therapeutic target New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima

Pathophysiology Neointimal Hyperplasia New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima

Treatment Vascular reconstruction Principal way to salvage failing grafts Based on assumption that renewed or continued intimal thickening is unlikely With regular follow-up, stenoses in vein grafts may be discovered prior to graft thrombosis If these lesions are reconstructed in time, long-term outcome is generally good

Treatment Neointimal Hyperplasia ASA, plavix, IIb/IIIa inhibitors New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima

Treatment Neointimal Hyperplasia New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima Heparin HELVETICA- In 1141 patients randomized to hirudin, heparin, or placebo, there was no difference in restenosis at 6 months. Coumadin BAAS- In 530 patients randomized to ASA or ASA/Coumadin, composite clinical endpoint was lower in ASA/Coumadin arm at 1 yr. However, Coumadin did not affect restenosis.

Pathophysiology Neointimal Hyperplasia New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima Oxidative stress promotes the expression of endothelial adhesion molecules (e.g. VCAM) that increase monocyte adhesion and transmigration. Probucol is an antioxidant drug.

Treatment Neointimal Hyperplasia New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima START trial: Brachytherapy Patients with in-stent stenosis randomized to radiation showed reduction of restenosis from 45% to 29% at 8 months compare to control. Intracoronary radiation reduces neointimal proliferation after PTCA, likely by inhibiting SMC proliferation and by inducing apoptosis.

Treatment Neointimal Hyperplasia New matrix synthesized Arterial injury Platelet adhesion/activation Thrombosis Thrombus develops endothelial layer Leukocytes demarginate from bloodstream, migrate into subendothelial mural thrombus Smooth muscle cells proliferate and migrate into intima MCAM is an Ig superfamily adhesion molecule expressed on endothelial cells and circulating endothelial precursors. It mediates cell adhesion and intracellular signal transduction.

Treatment Neointimal Hyperplasia MCAM deficiency abrogated neointimal hyperplasia in the carotid ligation model in mice. ? ? ? Wild-type MCAM-/-

Treatment Restenosis and Drug-Eluting Stents A. Rapamycin (Sirolimus): -A macrolide produced by Streptomyces hygroscopicus -Found in soil from Easter Island in Inhibits migration and proliferation of vascular smooth muscle cells -Anti-inflammatory properties

Treatment Restenosis and Drug-Eluting Stents A. Rapamycin: Rapamycin inhibits neointimal hyperplasia in porcine coronary restenosis model at 30 days. Gallo et.al. Circulation. 1999;99:2164

Treatment Restenosis and Drug-Eluting Stents B. Paclitaxel -An anti-neoplastic drug derived from Pacific yew tree. -Inhibits migration and proliferation by enhancing microtubule assembly.

Treatment Restenosis and Drug-Eluting Stents B. Paclitaxel TAXUS I -61 patients with de novo or restenotic lesions -Randomzed to TAXUS stent or bare metal Grube et.al. Circulation. 2003;107:38

Conclusion Intimal hyperplasia Intimal hyperplasia is a complex response to injury. Vascular reconstruction is effective in salvage of vein grafts if performed in time Antiplatelet agents are effective if given at or withing a short time of surgery Development of effective therapy requires an understanding of the underlying pathophysiology.